Compare · ALEC vs BNTX
ALEC vs BNTX
Side-by-side comparison of Alector Inc. (ALEC) and BioNTech SE (BNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALEC and BNTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $28.65B, about 108.7x ALEC ($263.5M).
- BNTX has been more active in the news (7 items in the past 4 weeks vs 4 for ALEC).
- Both have 25 recent analyst ratings on file.
- Company
- Alector Inc.
- BioNTech SE
- Price
- $2.36+2.61%
- $114.00+1.03%
- Market cap
- $263.5M
- $28.65B
- 1M return
- -
- +25.06%
- 1Y return
- -
- +8.83%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2019
- News (4w)
- 4
- 7
- Recent ratings
- 25
- 25
Alector Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest ALEC
- Chief Executive Officer Rosenthal Arnon gifted 1,050,000 shares and received a gift of 1,050,000 shares (SEC Form 4)
- SEC Form 10-Q filed by Alector Inc.
- Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
- Principal Accounting Officer Wong-Sarad Grace was granted 20,000 shares, increasing direct ownership by 21% to 115,461 units (SEC Form 4)
- Alector Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Director Scheller Richard H was granted 28,700 shares, increasing direct ownership by 27% to 134,899 units (SEC Form 4)
- Director Yaffe Kristine was granted 28,700 shares, increasing direct ownership by 30% to 124,109 units (SEC Form 4)
- Director Hammond Paula was granted 28,700 shares, increasing direct ownership by 38% to 103,609 units (SEC Form 4)
- Director Altmeyer Mark was granted 28,700 shares, increasing direct ownership by 41% to 98,650 units (SEC Form 4)
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
- Amendment: SEC Form 20-F/A filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union